Recherche sur le cancer

Applications 3-Bromopropionic-2,2,3,3-d4 Acid is the labeled analog of 3-Bromopropionic acid (B687705). 3-Bromopropionic Acid is used as a reagent in the synthesis of nitrogen containing diselenides which exhibit antioxidant activity. Also used as a reagent in the synthesis of indolin-2-one-based multi-targeted receptor tyrosine kinase inhibitors as potential anticancer agents.
References Nascimento, V., et al.: Eur. J. Med. Chem., 87, 131 (2014); Zhang, L., et al.: Eur. J. Med. Chem., 82, 139 (2014)

Applications (4E, 8Z)-Sphingadienine-C18-1-phosphate is an analogue of (4E, 14Z)-Sphingadienine-C18 (S680630), a sphingoid base of sea cucumber cerebroside that may have cytotoxicity activity against human colon cancer cells.
References Sugawara, T., et. al.: Biosci. Biotech. Bioch., 70, 2906 (2006)

Applications 4-Bromotoluene-d3 is isotopically labelled form of 4-Bromotoluene (B688235), which is used as a reagent in the preparation of aromatic diselenides that are useful for generating anticancer lead compounds.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Rizvi, M.A., et al.: Bioorg. Med. Chem. Lett., 24, 3440 (2014); Leung, C., et al.: Angew Chem., Int. Ed., 52, 766 (2013);

Applications D-2'-Deoxyribopyranosyl-3-guanylurea (α/β-Mixture) can be obtained from 5-Aza-2’-deoxy Cytidine (A796950) which can be used as cancer treatment, in particular to inhibit the growth of pancreatic endocrine tumor cell lines.
References Deng, T., et al.: Life Sci., 84, 311 (2009), Horne, H., et al.: Mol. Cancer Res., 7, 199 (2009), Zinner, R., et al.: Mol. Cancer Ther., 8, 521 (2009),

Applications rel-(R*,R*)-Bicalutamide Sulfoxide is an diastereomeric bicalutamide (B382000) derivative.
References Li, Wei., et al.: Chirality., 21, 578 (2009);

Applications CPI 613 is a class of non-redox-active lipoate derivative that disrupts cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Zachar, Z. et al.: J. Mol. Med., 89, 1137 (2011); Lee, K. et al.: Drug Met. Lett., 5, 163 (2011)

Impurity Anastrozole Diacid Impurity
Applications Anastroloze Diacid is a derivative of Anastrozole (A637425), an aromatase inhibitor. Used as an antineoplastic. Anastrozole Diacid Imp
References Plourde, P.V., et al.: Breast Cancer Res. Treat., 30, 103 (1994), Buzdar, A.U., et al.: Cancer, 79, 730 (1997)

Applications This compound acts as an autophagy inhibitor, which removes the protection of cancer cells from various biological stresses.
References McAfee, Q. et al.: P. Natl. Acad. Sci.. U.S.A., 109, 8253 (2012);

Applications Chloroethylnitrosourea derivative with antitumor activity. Similar to carmustine, chlorozotocin, nimustine, ranimustine. Antineoplastic.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Johnston, T.P., et al.: J. Med. Chem., 9, 892 (1966), Oliverio, V.T., et al.: Cancer Res., 30, 1330 (1970), Thompson, G.R., et al.: Toxicol. Appl. Pharmacol., 21, 405 (1972), Al-Shammary, F.J., et al.: Anal. Profiles Drug Subs., 19, 315 (1990),

Stability Light Sensitive
Applications A metabolite of Bexarotene (B336750).
References Hashimoto, S., et al.: Xenobiotica, 24, 1177 ( 1994), Boehm, M., et al.: J. Med. Chem., 38, 3146 (1995), Shirley, M.A., et al.: Drug Metab. Dispos., 25, 1144 (1997),

Applications 1-Chloro-1-desmethylpiperazinyl-bosutinib is a useful intermediate in the green preparation of the anti-tumor agent Bosutinib (B676095). It is a COVID19-related research product.
References Mao, Y., et al.: Synthesis, 47, 3133 (2015); Chen, H., et al.: Zhongguo Yiyao Gongye Zazhi, 44, 1086 (2013); Yin, X. J., et al.: Molecules, 4261 (2010)

Applications Used in the preparation of N-phenylcarboxamide derivatives as antitumor agents.

Stability Light Sensitive, Moisture Sensitive, Temperature Sensitive
Applications A major metabolite of Irinotecan.
References Canal, P., et al.: J. Clin. Oncol., 14, 2688 (1996), Haaz, M., et al.: Cancer Res., 58, 468 (1998), Kehrer, D., et al.: Clin. Cancer Res., 6, 3451 (2000), Hanioka, N., et al.: Xenobiotica, 31, 687 (2001), Satoh, T., et al.: Drug Metab. Dispos., 30, 488 (2002),